乌斯特基努马
医学
溃疡性结肠炎
维多利祖马布
内科学
队列
队列研究
加药
疾病
英夫利昔单抗
作者
Rahul S. Dalal,Scott Esckilsen,Edward L. Barnes,Jordan C. Pruce,Jenna Marcus,Jessica R. Allegretti
标识
DOI:10.1016/j.cgh.2021.03.028
摘要
Ustekinumab has been shown to be effective for the treatment of ulcerative colitis (UC); however, >40% of patients have suboptimal clinical response after induction and maintenance dosing every 8 weeks.1,2 The best management approach for these patients is unclear. Many undergo empiric dose intensification to every 4 weeks or every 6 weeks, a nonstandardized decision because of limited data supporting therapeutic drug monitoring of ustekinumab.3 In Crohn's disease, approximately 50% of patients undergo ustekinumab dose intensification, which seems to be effective based on prior work from our group and others.4-8 However, similar data in UC are lacking. In this real-world multicenter cohort study, we sought to identify predictors and outcomes of ustekinumab dose intensification in UC.
科研通智能强力驱动
Strongly Powered by AbleSci AI